Ivlan

Ivabradine, the active ingredient in Ivlan, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is used in the management of chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivlan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivlan (ivabradine) is indicated for conditions where reduction of heart rate improves clinical outcomes. - Chronic stable angina pectoris: reduces the frequency of angina attacks by lowering heart rate without affecting contractility. - Heart failure with reduced ejection fraction: decreases hospitalization risk by improving ventricular filling time through heart‑rate reduction. - Symptomatic angina despite optimal therapy: provides additional heart‑rate control to improve exercise tolerance.

Ivabradine may be associated with several adverse reactions, which are categorised by frequency.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: symptomatic slow heart rate. - Headache. - Dizziness.

Serious or Rare Side Effects: - Atrial fibrillation. - Severe bradycardia requiring intervention. - Allergic reactions (rash, angioedema).

When prescribing Ivlan, clinicians should consider the following precautions. - Initiate therapy only after confirming the indicated cardiovascular condition. - Monitor heart rate regularly; adjust dose if resting heart rate falls below 50 bpm. - Avoid use in patients with severe hepatic impairment. - Exercise caution in patients with pre‑existing atrial fibrillation. - Review concomitant medications that affect cardiac conduction. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Ivlan can interact with several medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine exposure. - Co‑administration with other bradycardic agents (beta‑blockers, digoxin): risk of excessive heart‑rate reduction. - QT‑prolonging drugs combined with ivabradine may raise arrhythmia risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine effectiveness. - Antidepressants affecting cardiac conduction (e.g., amitriptyline): monitor heart rate.